Journals / Dicle Tıp Dergisi / 2015 / Cilt: 42 - Sayı: 4

The frequency of polyneuropathy and comparison of laboratory parameters in patients with multiple myeloma

Multipl miyelomlu hastalarda polinöropati sıklığı ve laboratuvar parametrelerinin karşılaştırılması

Pages
445–448
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Presence or development of PN in MM and its readiness to be used as an early marker, will obviously facilitate the treatment and follow-up of MM.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Multiple myeloma(MM) is a B-cell neoplasia, characterized by clonal expansion of malignant plasma cells in bone marrow.
📊
Key Findings & Data:Methods: Totally 70 patients (31 male, 39 female) who presented to hematology outpatient department were retrospectively evaluated.
💡
Conclusion & Impact:Conclusion: Presence or development of PN in MM and its readiness to be used as an early marker, will obviously facilitate the treatment and follow-up of MM.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Multiple myeloma(MM) is a B-cell neoplasia, characterized by clonal expansion of malignant plasma cells in bone marrow. Polyneuropathy (PN) is the most important complications in the treatment of MM. The aim of our study is to find out whether the lab parameters and the incidence of PN, are markers in MM patients or not. Methods: Totally 70 patients (31 male, 39 female) who presented to hematology outpatient department were retrospectively evaluated. Pre-treatment laboratory parameters and electromyography records of the patients taken from the file. Results: 15.7% of the cases the diagnosis was immediately available PN. Levels of β2 microglubin, uric acid, total protein, calcium, ALT, AST, creatinine, LDH and albumin levels didn’t differ significantly between two groups (p>0.05). Conclusion: Presence or development of PN in MM and its readiness to be used as an early marker, will obviously facilitate the treatment and follow-up of MM.

Özet

Amaç: Multipl miyelom (MM), kemik iliğinde malign plazma hücrelerinin klonal ekspansiyonu ile karakterize bir B-hücre neoplazisidir. Polinöropati (PN), MM tedavisinin en önemli komplikasyonlarından biridir. Çalışmamızdaki amaç; MMli hastalarda tanı anındaki PN görülme sıklığı ve tedavi öncesi laboratuar parametrelerinin PN açısından belirteç olup olmadığını saptamaktı. Yöntemler: Çalışmaya hematoloji polikliniğinde takipli 31i erkek, 39u kadın olmak üzere toplam 70 olgu retrospektif olarak incelendi. Hastaların tedavi öncesi laboratuar parametreleri ve elektromiyografileri dosyalarından alındı. Bulgular: Olguların tanı anında %15.7inde PN mevcuttu. PNsi olan ve olmayan hastaların β2 mikroglobin, ürik asit, total protein, kalsiyum, ALT, AST, kreatinin, LDH ve albümin değerleri arasında anlamlı farklılık bulunmadı (p>0,05). Sonuç: MMde, PN varlığı veya gelişimini gösterebilen ve erken belirteç olarak kullanılabilecek bir parametre bulunması hastaların takip ve tedavisini kolaylaştıracağı görüldü.

🔖

Cite This Article

SAKİN, A., AYER, M., ÇELİK, K., BERKİL, F., ACAR, H., AYER, A., SAKİN, A., ŞAR, F. (2015). The frequency of polyneuropathy and comparison of laboratory parameters in patients with multiple myeloma. Dicle Tıp Dergisi, Cilt: 42 - Sayı: 4, 445–448. https://ajindex.com/articles/348850

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Decaux O, Laurat E, Perlat A, et al. Systemic manifestations of monoclonal gammopathy. Eur J Intern Med 2009;20:457-461.
  2. Ramchandren S, Lewis RA. Monoclonal gammopathy and neuropathy. Curr Opin Neurol 2009;22:480-485.
  3. Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 2012;26:595-608.
  4. Holland J, Trenkner DA, Wasserman TH, Fineberg B. Plasmacytoma. Treatment results and conversion to myeloma. Cancer 1992;69:1513-1517.
  5. Jemal A, Murray T, Samuels A, et al. Cancer Statistics. CA Cancer J Clin 2003;53:5-26.
  6. Antoine JC, Camdessanché JP. Peripheral nervous system involvement in patients with cancer. Lancet Neurol 2007;6:75-86.
  7. Denier C, Lozeron P, Adams D, et al. Multifocal neuropathy due to plasma cell infiltration of peripheral nerves in multiple myeloma. Neurology. 2006;66:917-918. Nobile-Orazio E. Neuropathy and monoclonal gammopathy. Handb Clin Neurol 2013;115:443-459.
  8. Silberman J, Lonial S. Review of peripheral neuropathy in plasma cell disorders. Hematol Oncol 2008;26:55-65.
  9. Kelly JJ, Kyle RA, O’Brien PC, Kohn J. Prevalence of monoclonal proteins in peripheral neuropathy. Neurology 1981; 31: 1480-1483.
  10. Reddy GK, Mughal TI, Lonial S. Optimizing the management of treatment-related peripheral neuropathy in patients with multiple myeloma. Support Cancer Ther 2006;4:19- 22. Ramchandren S, Lewis RA. Monoclonal gammopathy and neuropathy. Curr Opin Neurol 2009;22:480-485.